Clinical Trial Update: Study to Assess Safety,Tolerability,Pharmacokinetics & Antiviral Activity of JTK-853 in Hepatitis C Virus Genotype 1 Infected Subjects [Phase 1]

View source ↗

Summary

A Phase 1 study assessing safety, tolerability, pharmacokinetics, and antiviral activity of JTK-853 in Hepatitis C genotype 1–infected subjects has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• JTK-853

Snippet

Sponsor: Akros Pharma Inc. | Conditions: Hepatitis C Virus Infection, Response to Therapy of | Phase 1 | Status: COMPLETED